Immunovant, Inc.
IMVT · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $360,917 | $212,928 | $160,257 | $101,808 |
| G&A Expenses | $77,235 | $57,281 | $48,019 | $54,225 |
| SG&A Expenses | $77,235 | $57,281 | $48,019 | $54,225 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $438,152 | $270,209 | $208,276 | $156,033 |
| Operating Income | -$438,152 | -$270,209 | -$208,276 | -$156,033 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $25,203 | $11,440 | -$2,675 | -$781 |
| Pre-Tax Income | -$412,949 | -$258,769 | -$210,951 | -$156,814 |
| Tax Expense | $891 | $567 | $9 | -$84 |
| Net Income | -$413,840 | -$259,336 | -$210,960 | -$156,730 |
| % Margin | – | – | – | – |
| EPS | -2.73 | -1.88 | -1.71 | -1.43 |
| % Growth | -45.2% | -9.9% | -19.6% | – |
| EPS Diluted | -2.73 | -1.88 | -1.71 | -1.43 |
| Weighted Avg Shares Out | 151,574 | 138,100 | 123,075 | 109,679 |
| Weighted Avg Shares Out Dil | 151,574 | 138,100 | 123,075 | 109,679 |
| Supplemental Information | – | – | – | – |
| Interest Income | $24,732 | $24,948 | $7,578 | – |
| Interest Expense | $0 | $0 | $12,482 | – |
| Depreciation & Amortization | $377 | $231 | $193 | $126 |
| EBITDA | -$437,775 | -$269,978 | -$208,083 | -$155,907 |
| % Margin | – | – | – | – |